LEGN Stock Analysis: Legend Biotech | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.625m USD | 12M Return: -49.9% | US52490G1022 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 35.3M
Qual. Beats: 0
Rev. Trend: 98.9%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Legend Biotech Corporation (LEGN) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Somerset, New Jersey, that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other diseases across the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell (CAR-T) therapy designed to treat multiple myeloma (MM).
The companys pipeline extends beyond cilta-cel to include earlier-stage autologous CAR-T candidates targeting cancers such as acute lymphoblastic leukemia, gastric, esophageal, pancreatic, colorectal, and lung cancers, as well as allogeneic gamma delta CAR-T and CAR-NK product candidates directed at B-cell maturation antigen (BCMA) for MM, which are currently in investigator-initiated Phase 1 trials in China. Legend Biotech operates within a capital-intensive business model typical of the biotechnology sector, relying heavily on R&D investment, multi-year clinical development timelines, and regulatory approvals to bring therapies to market.
Key partnerships include a collaboration and license agreement with Janssen Biotech for the development and commercialization of cilta-cel, and a license agreement with Novartis Pharma AG for CAR-T cell therapies targeting delta-like ligand protein 3 (DLL3). The company went public on NASDAQ in June 2020 and is classified in the Health Care sector under the Biotechnology sub-industry.
- Carvykti sales surge as multiple myeloma demand expands
- Janssen partnership fuels global cilta-cel commercialization
- Abecma competition intensifies in BCMA-directed therapy market
| Net Income: -91.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 2.59 > 1.0 |
| NWC/Revenue: 64.80% < 20% (prev 123.5%; Δ -58.74% < -1%) |
| CFO/TA -0.10 > 3% & CFO -183.1m > Net Income -91.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (193.8m) vs 12m ago 5.25% < -2% |
| Gross Margin: 56.58% > 18% (prev 62.51%; Δ -5.94% > 0.5%) |
| Asset Turnover: 73.89% > 50% (prev 47.15%; Δ 26.74% > 0%) |
| Interest Coverage Ratio: -2.56 > 6 (EBIT TTM -43.1m / Interest Expense TTM 16.8m) |
| A: 0.47 (Total Current Assets 1.23b - Total Current Liabilities 403.6m) / Total Assets 1.75b |
| B: -1.13 (Retained Earnings -1.98b / Total Assets 1.75b) |
| C: -0.03 (EBIT TTM -43.1m / Avg Total Assets 1.72b) |
| D: 2.36 (Book Value of Equity 1.23b / Total Liabilities 521.3m) |
| Altman-Z'' = 1.71 = BBB |
| DSRI: 0.54 (Receivables 198.0m/229.0m, Revenue 1.27b/796.8m) |
| GMI: 1.10 (GM 62.51% / 56.58%) |
| AQI: 0.35 (AQ_t 0.04 / AQ_t-1 0.12) |
| SGI: 1.60 (Revenue 1.27b / 796.8m) |
| TATA: 0.05 (NI -91.6m - CFO -183.1m) / TA 1.75b) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of September 19, 2026, the stock is trading at USD 17.61 with a total of 2,932,820 shares traded. Over the past week, the price has changed by -5.53%, over one month by -19.66%, over three months by -36.95% and over the past year by -49.91%.
Current recommended Stop Loss: 16.20 (which is 8% or 1.4 ATR below the current price).
Legend Biotech has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LEGN.
- StrongBuy: 11
- Buy: 10
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 48.5 | 175.3% |
P/E Forward = 28.6533
P/S = 2.8514
P/B = 3.0361
Revenue TTM = 1.27b USD
EBIT TTM = -43.1m USD
EBITDA TTM = -7.24m USD
Long Term Debt = 110.0m USD (estimated: total debt 278.2m - short term 168.2m)
Short Term Debt = 168.2m USD (from shortTermDebt, last quarter)
Debt = 400.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 121.8m
Net Debt = -564.6m USD (calculated: Debt 400.0m - CCE 964.6m)
Enterprise Value = 3.06b USD (3.63b + Debt 400.0m - CCE 964.6m)
Interest Coverage Ratio = -2.56 (Ebit TTM -43.1m / Interest Expense TTM 16.8m)
EV/FCF = -11.98x (Enterprise Value 3.06b / FCF TTM -255.6m)
FCF Yield = -8.35% (FCF TTM -255.6m / Enterprise Value 3.06b)
FCF Margin = -20.10% (FCF TTM -255.6m / Revenue TTM 1.27b)
Net Margin = -7.21% (Net Income TTM -91.6m / Revenue TTM 1.27b)
Gross Margin = 56.58% ((Revenue TTM 1.27b - Cost of Revenue TTM 552.1m) / Revenue TTM)
Gross Margin QoQ = 64.54% (prev 42.35%)
Tobins Q-Ratio = 1.75 (Enterprise Value 3.06b / Total Assets 1.75b)
Interest Expense / Debt = 4.21% (Interest Expense 16.8m / Debt 400.0m)
Taxrate = 40.18% (22.3m / 55.5m)
NOPAT = -25.8m (EBIT -43.1m * (1 - 40.18%)) [loss with tax shield]
Current Ratio = 3.04 (Total Current Assets 1.23b / Total Current Liabilities 403.6m)
Debt / Equity = 0.33 (Debt 400.0m / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = 77.94 (negative EBITDA) (Net Debt -564.6m / EBITDA -7.24m)
Debt / FCF = 2.21 (negative FCF - burning cash) (Net Debt -564.6m / FCF TTM -255.6m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.32% (Net Income -91.6m / Total Assets 1.75b)
RoE = -8.70% (Net Income TTM -91.6m / Total Stockholder Equity 1.05b)
RoCE = -3.71% (EBIT -43.1m / Capital Employed (Equity 1.05b + L.T.Debt 110.0m))
RoIC = -1.78% (negative operating profit) (NOPAT -25.8m / Invested Capital 1.45b)
WACC = 9.16% (E(3.63b)/V(4.03b) * Re(9.89%) + D(400.0m)/V(4.03b) * Rd(4.21%) * (1-Tc(0.40)))
Discount Rate = 9.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.26 | Cagr: 2.83%
[DCF] Fair Price = unknown (Cash Flow -255.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.10 | # QB: 0
Revenue Correlation: 98.92 | Revenue CAGR: 84.22% | SUE: 1.41 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.01 | Chg30d=-90.00% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.01 | Chg30d=-103.31% | Revisions=-25% | GrowthEPS=+99.4% | GrowthRev=+39.4%
EPS next Year (2027-12-31): EPS=0.81 | Chg30d=-29.24% | Revisions=-25% | GrowthEPS=+9835.3% | GrowthRev=+26.3%
[Analyst] Revisions Ratio: -50% (up=0, down=3)